Standard BioTools Inc. Secured Debt
Standard BioTools Inc. (LAB) had Secured Debt of $9.39 million as of 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:SecuredDebt · last filed 2022-11-09
- 2022-09-30: Secured Debt $9.39M.
- 2022-06-30: Secured Debt $10.16M.
- 2022-03-31: Secured Debt $10.11M.
- 2021-12-31: Secured Debt $10.05M.
| Period end | Secured Debt |
|---|---|
| 2022-09-30 | $9.39M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $10.16M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $10.11M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $10.05M 10-Q · filed 2022-11-09 |
| 2021-09-30 | $9.99M 10-Q · filed 2021-11-09 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |